Targeting type-2 inflammation in pulmonary hypertension: lessons from a novel model.
作者信息
Singh Navneet, Oldham William M
机构信息
Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, The Warren Alpert School of Medicine, Brown University, Providence, Rhode Island, United States.
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States.
出版信息
Am J Physiol Lung Cell Mol Physiol. 2025 May 1;328(5):L669-L670. doi: 10.1152/ajplung.00109.2025. Epub 2025 Apr 7.
Abstract
摘要
相似文献
1
Targeting type-2 inflammation in pulmonary hypertension: lessons from a novel model.靶向肺动脉高压中的2型炎症：来自新型模型的经验教训。
Am J Physiol Lung Cell Mol Physiol. 2025 May 1;328(5):L669-L670. doi: 10.1152/ajplung.00109.2025. Epub 2025 Apr 7.
2
Pulmonary vascular remodeling in Fra-2 transgenic mice is driven by type 2 inflammation and accompanied by pulmonary vascular hyperresponsiveness.Fra-2转基因小鼠的肺血管重塑由2型炎症驱动，并伴有肺血管高反应性。
Am J Physiol Lung Cell Mol Physiol. 2025 Mar 1;328(3):L413-L429. doi: 10.1152/ajplung.00274.2024. Epub 2025 Feb 4.
3
Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis.Fra-2 转基因小鼠作为一种与系统性硬皮病相关的肺动脉高压新型模型。
Ann Rheum Dis. 2012 Aug;71(8):1382-7. doi: 10.1136/annrheumdis-2011-200940. Epub 2012 Apr 20.
4
Transcription factor Fra-2 and its emerging role in matrix deposition, proliferation and inflammation in chronic lung diseases.转录因子 Fra-2 及其在慢性肺部疾病中基质沉积、增殖和炎症中的新作用。
Cell Signal. 2019 Dec;64:109408. doi: 10.1016/j.cellsig.2019.109408. Epub 2019 Aug 29.
5
Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1.通过涉及转录因子Fra-2/AP-1的途径发展肺纤维化。
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10525-30. doi: 10.1073/pnas.0801414105. Epub 2008 Jul 18.
6
Transforming growth factor-β plays divergent roles in modulating vascular remodeling, inflammation, and pulmonary fibrosis in a murine model of scleroderma.在硬皮病小鼠模型中，转化生长因子-β在调节血管重塑、炎症和肺纤维化方面发挥着不同作用。
Am J Physiol Lung Cell Mol Physiol. 2017 Jan 1;312(1):L22-L31. doi: 10.1152/ajplung.00428.2016. Epub 2016 Nov 18.
7
Fra-1/AP-1 transcription factor negatively regulates pulmonary fibrosis in vivo.Fra-1/AP-1 转录因子负向调控体内肺纤维化。
PLoS One. 2012;7(7):e41611. doi: 10.1371/journal.pone.0041611. Epub 2012 Jul 24.
8
IL-1 receptor blockade skews inflammation towards Th2 in a mouse model of systemic sclerosis.白细胞介素-1 受体阻断在系统性硬化症小鼠模型中使炎症向 Th2 倾斜。
Eur Respir J. 2019 Sep 29;54(3). doi: 10.1183/13993003.00154-2019. Print 2019 Sep.
9
T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis.T 细胞共刺激阻断在实验性消化和肺组织纤维化中有效。
Arthritis Res Ther. 2018 Aug 29;20(1):197. doi: 10.1186/s13075-018-1694-9.
10
Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension.泛 PPAR 激动剂 IVA337 对实验性肺纤维化和肺动脉高压有效。
Ann Rheum Dis. 2017 Nov;76(11):1931-1940. doi: 10.1136/annrheumdis-2016-210821. Epub 2017 Aug 11.
本文引用的文献
1
Pulmonary vascular remodeling in Fra-2 transgenic mice is driven by type 2 inflammation and accompanied by pulmonary vascular hyperresponsiveness.Fra-2转基因小鼠的肺血管重塑由2型炎症驱动，并伴有肺血管高反应性。
Am J Physiol Lung Cell Mol Physiol. 2025 Mar 1;328(3):L413-L429. doi: 10.1152/ajplung.00274.2024. Epub 2025 Feb 4.
2
Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension.孟德尔随机化与实验医学方法靶向白细胞介素-6治疗肺动脉高压
Eur Respir J. 2022 Mar 10;59(3). doi: 10.1183/13993003.02463-2020. Print 2022 Mar.
3
Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial.利妥昔单抗治疗系统性硬化症相关肺动脉高压的安全性和疗效：一项多中心、双盲、随机、安慰剂对照试验。
Am J Respir Crit Care Med. 2021 Jul 15;204(2):209-221. doi: 10.1164/rccm.202009-3481OC.
4
Transcription factor Fra-2 and its emerging role in matrix deposition, proliferation and inflammation in chronic lung diseases.转录因子 Fra-2 及其在慢性肺部疾病中基质沉积、增殖和炎症中的新作用。
Cell Signal. 2019 Dec;64:109408. doi: 10.1016/j.cellsig.2019.109408. Epub 2019 Aug 29.
5
Screening for pulmonary arterial hypertension in systemic sclerosis.系统性硬皮病患者的肺动脉高压筛查。
Eur Respir Rev. 2019 Jul 31;28(153). doi: 10.1183/16000617.0023-2019. Print 2019 Sep 30.
6
IL-1 receptor blockade skews inflammation towards Th2 in a mouse model of systemic sclerosis.白细胞介素-1 受体阻断在系统性硬化症小鼠模型中使炎症向 Th2 倾斜。
Eur Respir J. 2019 Sep 29;54(3). doi: 10.1183/13993003.00154-2019. Print 2019 Sep.
7
Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension.肺动脉高压发病机制中的炎症与免疫。
Circ Res. 2014 Jun 20;115(1):165-75. doi: 10.1161/CIRCRESAHA.113.301141.
8
Anti-inflammatory and immunosuppressive agents in PAH.肺动脉高压中的抗炎和免疫抑制药物。
Handb Exp Pharmacol. 2013;218:437-76. doi: 10.1007/978-3-642-38664-0_18.
9
Systemic sclerosis-associated pulmonary arterial hypertension.系统性硬皮病相关肺动脉高压。
Chest. 2013 Oct;144(4):1346-1356. doi: 10.1378/chest.12-2396.
10
The potential of biologics for the treatment of asthma.生物制剂治疗哮喘的潜力。
Nat Rev Drug Discov. 2012 Dec;11(12):958-72. doi: 10.1038/nrd3792.
Zotero 插件